Novavax Vaccine Could Help Reduce Vaccine Hesitancy If Approved

Novavax has finally concluded their submission seeking provisional approval of their COVID-19 vaccine. The Novavax vaccine is a more ‘traditional’ protein sub-unit vaccine that could help increase vaccination rates amongst those sceptical of the mRNA and viral vector vaccine technology. So far, phase 3 clinical trials have shown promising results – an efficacy of 90.4% against illness and 100% protection against severe illness amongst 30,000 participants.

The federal government expects Novavax doses to arrive this month. However, they will not be rolled out until approval is received from the medical regulator. The doses will hopefully encourage more people to get vaccinated, and help with the booster shot program.